🔗 Share this article

As the United States undertakes sweeping adjustments to its immunization schedules, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by questioning COVID-19 vaccines in the global health crisis and has zeroed in on possible deaths following COVID-19 vaccination in her recent position at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Public health authorities planned to unveil radical changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s national calendar, sources say – a significant shift that would place the US out of alignment with a large portion of the world with no evidence for public health gain. This reveal has been delayed until the new year.

Rather than the director of the vaccine center, Høeg is set to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to lead the center this year.

A Shift at the Agency

The acting appointment may indicate a strengthened alliance between the drug and biologics divisions as Høeg and Dr. Prasad solidify control at the agency – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric shot schedules in the US so as to align more like Denmark, a country with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

To date statements, she has continued to focus on immunizations – usually the domain of Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Qualifications

Dr. Høeg has no apparent background in medication creation, regulation or leadership, which has been customary for former heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in running a major agency. She has no expertise in drug approvals.”

Previous directors of the center would “grasp legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who led CBER have had.”

The drug center has an vast workload at the FDA, Woodcock pointed out.

“The public just zeroes in on the new drug program, but the off-patent medication office authorizes a multitude of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and more, and each of these have to be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

There is also, a major leadership component to the job, which manages more than 5,000 staff members. “It is a massive administrative position, if you do it right,” the former official added.

Response and Contentious Initiatives

In response to questions about Dr. Høeg's qualifications and whether this appointment signifies increased cooperation among regulatory chiefs on immunizations, a representative stated that the “questions rely on flawed assumptions”.

“Her experience aligns with the functions of her position,” the spokesperson explained, noting the period Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed expedited drug-approval program that reportedly concerned her predecessors. “By what process are these medications being selected for this voucher program? Who makes the decisions?” Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he stated, “the agency looks to be trending towards laxer rules of pharmaceuticals, except for shots.”

Established History on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, track record, some experts said. She authored a study using non-validated crowd-sourced reports to estimate the frequency of myocarditis after COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the incoming administration encompassed revising guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she stated post-election on a podcast. At the agency, Høeg has according to sources floated the idea of barring teenage boys from receiving Covid vaccinations.

“She’s an thorough ideologue who commences with her beliefs and tailors the evidence to fit the science in a highly deceptive, fraudulent way,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other skeptics, {like|